UniPharma Co., Ltd.
UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and f… Read more
UniPharma Co., Ltd. (6621) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.112x
Based on the latest financial reports, UniPharma Co., Ltd. (6621) has a cash flow conversion efficiency ratio of -0.112x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-28.15 Million) by net assets (NT$251.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
UniPharma Co., Ltd. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how UniPharma Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
UniPharma Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UniPharma Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
|
0.009x |
|
Silvair Inc
WAR:SVRS
|
0.106x |
|
Pelangio Exploration Inc
PINK:PGXPF
|
-0.834x |
|
Jaya Agra Wattie Tbk
JK:JAWA
|
0.023x |
|
FuelPositive Corp
OTCQB:NHHHF
|
0.001x |
|
AMJ Global Technology
PINK:AMJT
|
0.014x |
|
Arcure SA
PA:ALCUR
|
0.207x |
|
Mega Manunggal Property TBK PT
JK:MMLP
|
0.000x |
Annual Cash Flow Conversion Efficiency for UniPharma Co., Ltd. (2019–2024)
The table below shows the annual cash flow conversion efficiency of UniPharma Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$284.75 Million | NT$-14.32 Million | -0.050x | -230.64% |
| 2023-12-31 | NT$312.67 Million | NT$12.03 Million | 0.038x | +136.87% |
| 2022-12-31 | NT$303.24 Million | NT$-31.65 Million | -0.104x | -140.16% |
| 2021-12-31 | NT$297.57 Million | NT$-12.93 Million | -0.043x | +4.12% |
| 2020-12-31 | NT$378.98 Million | NT$-17.18 Million | -0.045x | -96.80% |
| 2019-12-31 | NT$401.20 Million | NT$-9.24 Million | -0.023x | -- |